Single Cell Multiomics Market Report 2025

This single cell multiomics market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The single cell multiomics market size has grown exponentially in recent years. It will grow from $3.97 billion in 2024 to $4.85 billion in 2025 at a compound annual growth rate (CAGR) of 22.1%. The growth in the historic period can be attributed to an increase in research funding, rise in demand for personalized medicine, a growth in cancer research, an increase in the prevalence of chronic diseases, and a growth in academic and clinical research.

The single cell multiomics market size is expected to see exponential growth in the next few years. It will grow to $10.69 billion in 2029 at a compound annual growth rate (CAGR) of 21.8%. The growth in the forecast period can be attributed to growing adoption of precision medicine, increasing focus on rare diseases, growing interest in stem cell research, increasing clinical research studies, and rising demand for high throughput screening. Major trends in the forecast period include the development of multiparameter profiling tools, advancements in spatial transcriptomics, adoption of high resolution imaging techniques, adoption of integrated omics databases, and the development of advanced bioinformatics solutions.

The rising demand for precision medicine is expected to drive the growth of the single-cell multiomics market. Precision medicine involves customizing medical treatments and healthcare strategies to fit the unique characteristics of each patient. This growth is supported by advancements in genomic research, improved data analysis capabilities, and a deeper understanding of the benefits of personalized healthcare. Single-cell multiomics provides in-depth insights into cellular diversity and molecular mechanisms, facilitating the creation of highly personalized treatments based on individual cellular profiles. For example, the Personalized Medicine Coalition reported that in 2022, 12 new personalized medicines were approved, accounting for about 34% of all new therapies, reflecting a significant increase from previous years. This rising demand for precision medicine is fueling the expansion of the single-cell multiomics market.

Leading companies in the single-cell multiomics market are focusing on developing advanced single-cell multiomics tests to improve the precision and detail of cellular analysis. These tests allow researchers to gain a better understanding of complex biological processes, identify rare cell populations, and tailor precision medicine strategies by integrating detailed molecular data from individual cells. For instance, in June 2024, Mission Bio, a US-based biotechnology firm, introduced the Tapestri Single-cell Multiple Myeloma Multiomics Solution. This tool provides comprehensive profiling of multiple myeloma at the single-cell level, enabling researchers and drug developers to thoroughly analyze the molecular and cellular landscape during disease progression, understand therapy resistance, and identify disease drivers from early stages such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

In March 2022, Singleron Biotechnologies, a molecular diagnostics company based in Germany, acquired Proteona for an undisclosed sum. This acquisition aims to broaden Singleron’s global presence and enhance its capabilities in advanced single-cell multiomics technologies. The move is expected to strengthen Singleron’s position and utilize the expanded network to advance precision medicine and the clinical applications of single-cell technologies. Proteona, headquartered in Singapore, specializes in single-cell multiomics and integrates single-cell proteogenomic analysis with machine learning techniques.

Major companies operating in the single cell multiomics market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Illumina Inc., BioRad Laboratories Inc., QIAGEN N.V., BioTechne Corporation, Miltenyi Biotec BV & Co KG, BGI Genomics Co Ltd, 10x Genomics Inc., Molecular Devices LLC, NanoString Technologies Inc., Standard BioTools Inc., Akoya Biosciences Inc., Takara Bio Inc., Synthego Corporation, Mission Bio Inc., DeepCell Inc., RareCyte Inc., Parse Biosciences Inc., Dolomite Bio Ltd, Stilla Technologies SAS, NanoCellect Biomedical Inc., Epicypher Inc., Scipio Biosciences SAS.

North America was the largest region in the single cell multiomics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single cell multiomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single cell multiomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Single-cell multiomics is a sophisticated method that combines various molecular data types, including genomics, transcriptomics, proteomics, and metabolomics, at the level of individual cells. This approach offers a thorough perspective on cellular diversity and functionality, leading to more accurate understanding of complex biological processes and disease mechanisms.

The key segments in the single-cell multiomics market include single-cell genomics, single-cell proteomics, single-cell transcriptomics, and single-cell metabolomics. Single-cell genomics focuses on analyzing the entire genetic material (DNA) within a single cell. Techniques involved are single-cell isolation and dispensing, and single-cell analysis, with applications spanning oncology, cell biology, neurology, immunology, and stem cell research. End users of these technologies include academic institutions, contract research organizations, and pharmaceutical and biotech companies.

The single cell multiomics market research report is one of a series of new reports that provides single cell multiomics market statistics, including the single cell multiomics industry global market size, regional shares, competitors with single cell multiomics market share, detailed single cell multiomics market segments, market trends, and opportunities, and any further data you may need to thrive in the single cell multiomics industry. These single cell multiomics market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The single cell multiomics market consists of revenues earned by entities by providing services such as single-cell RNA sequencing, cellular imaging, and integrated multiomics solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The single cell multiomics market also includes sales of single cell isolation instruments, library preparation kits, and proteomics assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.